Speaker Profile
Markus Hartenbach

Markus Hartenbach MD

Nuclear Medicine, Radiology
Wien, Wien, Austria

Connect with the speaker?

Markus Hartenbach has graduated as a medical physician in 2005 at the University of Ulm and gained his doctoral degree in 2006 already in the field of prostate cancer research (topic: "[11C] choline PET / CT in primary prostate cancer"). Hartenbach is a certified specialist for clinical trials by the Competence Center for Clinical Trials of the University of Tübingen. He developed and conducted as principal investigator the prospective clinical phase III trial on combined [18F]Fluoroethylcholine(FEC)-PET/MRI in primary prostate cancer (EudraCT no .: 2006-003933-33; Clinical Trials.gov NCT00520546) which served as the reference trial for the official authorization of this radiopharmaceutical in several European countries. After taking the position of the divisional head of the PET/MRI unit at the Medical University of Vienna in 2014, he developed and established the prospective randomized clinical phase III trial on 68Ga-PSMAHBED-CC conjugate 11 in primary prostate cancer on an integrated PET/MRI system (RAPID study; clinicaltrials.gov: NCT02611882; EudraCT 2014-004758-33) which was launched in 2016. He is a founding member of the Ludwig Boltzmann Institute for Applied Diagnostics, which was granted in 2015, being responsible for prostate cancer imaging in the clinical trial track of this institute.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)